Pharmacogenetic Association Study of Warfarin Safety Endpoints in Puerto Ricans

摘要: Objective: This study was intended to determine the incidence rate of warfarinrelated adverse events (e.g., bleeding) in Puerto Ricans and whether a genetic association between warfarin pharmacogenes any these observed over initiation period (i.e., first 90 days therapy). Methods: We conducted an observational, retrospective cohort pharmacogenetic 122 warfarin-treated, male, Rican patients (69.9 ±9.6 years) from Veterans Affair Caribbean Healthcare System (VACHS) who consented participate. Genotyping performed using CYP2C9 VKORC 1 assays by Luminex. Event-free survival curves were estimated Kaplan‒Meier method analyzed log-rank test. Cox regression models constructed hazard ratios (HR) calculated. Results: Carriers functional VKORC1 polymorphisms demonstrated higher multiple 5.2 vs. 1.0 cases per 100 patient-months; RR = 4.8, p 0.12) than did wild types. A significant carrier status (HR 2.5; 95% CI : 1.0‒6.3, 0.04). However, no associations genotypes individual outcomes therapy found. Conclusion: The risks for due exposure examined time Ricans. Despite lack with this population, our findings revealed potential utility genotyping prevention during therapy.